Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. - Wikidata - wikimedia - TriplyDB

Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.

Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.

http://www.wikidata.org/entity/Q33305773

about

Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer Progress of molecular targeted therapies for prostate cancers Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging.Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition.EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway Gene expression pathways of high grade localized prostate cancer.Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output.MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays.Propagation of human prostate cancer stem-like cells occurs through EGFR-mediated ERK activation.Effect of acute exercise on prostate cancer cell growth Inhibition of both EGFR and IGF1R sensitized prostate cancer cells to radiation by synergistic suppression of DNA homologous recombination repair A two-step toward personalized therapies for prostate cancer ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients Both epidermal growth factor and insulin-like growth factor receptors are dispensable for structural intestinal adaptation.P2Y2 Receptor and EGFR Cooperate to Promote Prostate Cancer Cell Invasion via ERK1/2 Pathway mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.Mechanism of β-catenin-mediated transcriptional regulation of epidermal growth factor receptor expression in glycogen synthase kinase 3 β-inactivated prostate cancer cells Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes.EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1.Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma.Combined analysis of chromosomal instabilities and gene expression for colon cancer progression inference.Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer.Pharmacotherapeutic management of locally advanced prostate cancer: current status.Membrane proteins: the key players of a cancer cell.Prognostic determinants in prostate cancer.The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors.64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.Preclinical activity of multiple-target gold(III)-dithiocarbamato peptidomimetics in prostate cancer cells and xenografts.Modulation of RTK by sEcad: a putative mechanism for oncogenicity in oropharyngeal SCCs.PHLPPing through history: a decade in the life of PHLPP phosphatases.

P2860

Q26766638-931DE895-3019-4B64-BDDE-21BA4A621379 Q26823014-88AA9A17-7941-4061-8B1D-206D69BC28B3 Q30489312-EAE45267-B381-422E-984D-D782F2FFD535 Q30511916-9B5FD539-E208-4C45-B746-C109FF332725 Q31049380-56EBF25B-5EC8-49A4-AB97-FB4A33654C89 Q33383797-B4F3A669-19BD-41D2-AA8D-23720B8F2AEB Q33670486-9B9D2A4C-D91A-4E28-88CC-BD692DD914B9 Q33677975-59E56A4A-A980-41EC-B31C-8B780A4284E5 Q33766326-9C1A33AB-A033-428C-993B-1507EA5AC7B2 Q33779303-CE1DA265-E231-4595-8304-848C73F01835 Q33816577-CC3B1CDF-1487-4A37-8AB5-DF17A5022F46 Q33832517-4FE1E717-BF7C-4F92-B2E3-FA042E9F04CF Q33977056-719F7AFC-0ECC-4892-9C9E-880200125163 Q34281240-25492DC1-7835-465A-B3A3-97B8F6ED87F4 Q34574636-1E16DE69-B685-4143-AA92-59C09B4AFDEF Q34689170-72EDF9A3-80EF-48A3-9C1D-F22D8DB07846 Q34825681-FC64F679-BEA6-4380-AF98-99001A35D976 Q34946047-30E5DECC-F6F5-49F0-8A19-EFFF237D9743 Q34952878-6C6F839E-AB3B-4A9A-A94F-1A3420EB151E Q35091321-994BF746-4058-4B92-808A-83DBCB5BF095 Q35630090-61A08E27-EDD2-419E-B324-0554A83C88AE Q35693663-8E55C4E9-5CB2-47D9-AA40-64E439EA8672 Q35921941-8D4EC1D9-6CB3-410D-9421-F75A00924396 Q36002945-BDA3B624-04B4-48B7-9BC1-2484FA0EECBB Q36010700-005536BE-F51F-40D0-873E-8E74CF90CB63 Q37007828-DCC6FDC0-739D-4D44-B902-4CF6D98F9608 Q37125328-AB7130C7-0EF0-459E-9055-32A8B45B8B28 Q37198249-CE697218-F617-458F-8624-085CB3047B20 Q37597565-A34BA1AA-BC80-4199-8C9B-73AB308CCCD8 Q37688542-AE13C6A6-5AA2-44AE-B458-4A8ABCF0CFA4 Q37888666-B5558BAB-83E3-4033-BED3-0F194842C0A8 Q37898014-E95FB062-A142-40A2-9A6D-6F4B7140A5EB Q37966912-5F96EE4C-31F9-4DD1-A7A4-DA000D48D0BB Q38063121-208F2674-AC05-49F0-9E3F-510B882568BB Q38262816-86862999-A3CB-4242-A028-C89D7795255C Q38399733-DEF763C4-035B-4AE2-A2B3-3CC7BA4BA618 Q38815325-F49E2F8A-876F-4F96-B59B-01FA0DC140F5 Q38962397-9884630C-89A3-44A3-AE61-AD68653C43B9 Q39017078-DB83E1EE-4285-40BE-AD3E-E3C1D2469549 Q39027993-3A8F5DEF-DD6A-4E34-858A-E57B99207720

P2860

Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.

http://www.wikidata.org/entity/Q33305773

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Clinical significance of epide ...... mber gains in prostate cancer.

@ast

Clinical significance of epide ...... mber gains in prostate cancer.

@en

Clinical significance of epide ...... mber gains in prostate cancer.

@nl

type

label

Clinical significance of epide ...... mber gains in prostate cancer.

@ast

Clinical significance of epide ...... mber gains in prostate cancer.

@en

Clinical significance of epide ...... mber gains in prostate cancer.

@nl

prefLabel

Clinical significance of epide ...... mber gains in prostate cancer.

@ast

Clinical significance of epide ...... mber gains in prostate cancer.

@en

Clinical significance of epide ...... mber gains in prostate cancer.

@nl

P1433

Q33305773-88C8A6CD-FC7D-4616-823F-BD82C2F0E68B

P1476

Q33305773-174360EA-02C2-4FA0-AF14-58E502821636

P2093

Q33305773-14D6321B-C047-4DB4-B2D3-6C9AA06CD34E

Q33305773-1DFA290C-2D30-48F2-89E0-D1692A64B51D

Q33305773-2E0A1255-B380-4717-8611-FC08D6C6DB79

Q33305773-54076BFC-5E88-4D0A-8FB9-229632DEBAAF

Q33305773-916A2D5E-3866-44C3-A365-B5A4842AC733

Q33305773-AD5392B1-6535-493D-A210-ACEFD84BED18

Q33305773-AE519993-3C71-42E6-863B-34A4CEA593D8

Q33305773-D1469358-11F1-4263-A3CF-0DBDE8326C21

Q33305773-D7E0CC8A-8B72-49FD-8D5F-7E5F51CBA557

Q33305773-D7E6756F-1423-4AC1-8302-57866761C6CC

P304

Q33305773-68A9DB37-D95A-4C35-977F-4353053591D1

P31

Q33305773-0706D3CB-3BA3-4A3A-85DD-2FD44C1B3193

P356

Q33305773-C306C56D-C846-4678-9800-0E009963B1AE

P407

Q33305773-33C77AF2-CB85-4C7A-BADB-8F1C0ABDBEA3

P433

Q33305773-7FE1F8FA-005F-47ED-97B0-823AEC6D95E1

P478

Q33305773-B6324C14-150B-4791-83B2-FC601FBA4EC0

P50

Q33305773-EA9D2D14-EC71-46AC-9E37-B11891B4A2B5

P577

Q33305773-D6A767BA-03B4-4750-9003-590F660CB784

P5875

Q33305773-DEE811B7-83E3-4960-9FFE-3221F326985F

P698

Q33305773-A008A88E-FF99-46BC-9D58-83B17C5C90C2

P921

Q33305773-4388AC2A-AF0E-458B-B3FD-B11FEC20D260

P356

1078-0432.CCR-07-1257

P1433

Clinical Cancer Research

P1476

Clinical significance of epide ...... mber gains in prostate cancer.

@en

P2093

Alexander Haese

http://www.w3.org/2001/XMLSchema#string

Andreas Erbersdobler

http://www.w3.org/2001/XMLSchema#string

Birte Daniel

http://www.w3.org/2001/XMLSchema#string

Felix H K Chun

http://www.w3.org/2001/XMLSchema#string

Guido Sauter

http://www.w3.org/2001/XMLSchema#string

Hartwig Huland

http://www.w3.org/2001/XMLSchema#string

Jens Kollermann

http://www.w3.org/2001/XMLSchema#string

Jochen Walz

http://www.w3.org/2001/XMLSchema#string

Liv Iwers

http://www.w3.org/2001/XMLSchema#string

Markus Graefen

http://www.w3.org/2001/XMLSchema#string

P304

6579-6584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-1257

http://www.w3.org/2001/XMLSchema#string

P407

P433

22 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5839827

http://www.w3.org/2001/XMLSchema#string

P698

18006757

http://www.w3.org/2001/XMLSchema#string

P921